Celldex at guggenheim conference: barzolvolimab nears launch

On 09 November 2026, Celldex (CLDX) shared its case for barzolvolimab at the 3rd Annual Guggenheim Healthcare Innovation Conference. The monoclonal antibody aims to treat chronic spontaneous urticaria (CSU), a condition with few advanced therapy options. Celldex highlighted strong Phase III data, a large unmet need, and the drug's potential to reshape CSU treatment.

Barzolvolimab demonstrated a high complete response rate in the majority of patients in the studies, making it the first treatment to prospectively show angioedema clearing at 12 weeks. The drug offers two dosing options, Q8 (seven doses per year) and Q4 (four doses per year), which could lower the cost for payers.

Celldex reported $650 million in cash as of Q3, enough to fund operations through 2028 and the initial launch of barzolvolimab. The company noted that CSU remains underdiagnosed and undertreated, with fewer than 20% of eligible patients receiving advanced therapies. Novartis estimates a $4 billion market for CSU treatments, leaving room for expansion.

The company sees two main patient groups for barzolvolimab: first-line patients with severe disease or severe angioedema, and second-line patients not adequately controlled on existing treatments. Management emphasized the value of a therapy with deeper and more durable responses, as well as the potential for premium, value-based pricing.